The Healthy Hair Act amends the Federal Food, Drug, and Cosmetic Act to classify hair straightening and smoothing products that contain formaldehyde or formaldehyde‑releasing substances as adulterated. The statutory definition covers products intended to straighten, relax, smooth, or otherwise alter hair texture and explicitly includes keratin treatments.
The change takes effect for cosmetics introduced into interstate commerce 180 days after enactment.
The bill also directs the Food and Drug Administration, in consultation with NIOSH, to conduct a study on short‑ and long‑term health impacts of exposure to these products — with a focus on salon workers and links to cancer, respiratory disease, and endocrine disruption — and to deliver an initial report within one year and a final report within roughly two years. For manufacturers, importers, salon operators, and occupational‑health stakeholders, the Act would create immediate compliance, testing, and marketplace implications while concentrating federal attention on this category of products.
At a Glance
What It Does
The bill amends section 601 of the FD&C Act to add any hair straightening or smoothing product that contains formaldehyde or a formaldehyde‑releasing substance to the list of adulterated products. It also defines 'hair straightening or hair smoothing product' and sets an effective date 180 days after enactment for goods entering interstate commerce.
Who It Affects
Cosmetics manufacturers and importers of hair‑smoothing and keratin treatments, distributors and retailers that sell those products, salon owners and their workers who apply them, and federal agencies tasked with enforcement and occupational health research.
Why It Matters
The amendment creates a zero‑tolerance rule at the federal level for this product class, bringing FDA enforcement authorities to bear and concentrating federal research resources on occupational exposure risks — particularly for salon workers, a workforce often composed of women and people of color.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill changes federal law so that any hair straightening or smoothing product that contains formaldehyde or a chemical that releases formaldehyde is treated as 'adulterated' under the Federal Food, Drug, and Cosmetic Act. That labels this category of cosmetics as falling into an existing statutory bucket that triggers the suite of FDA authorities applicable to adulterated products.
The statutory definition is deliberately broad: it covers any product intended to straighten, relax, smooth, or otherwise alter hair texture and explicitly calls out keratin treatments.
Critically, the text uses 'any amount' of formaldehyde or a formaldehyde‑releasing substance, which is a literal zero‑tolerance standard rather than a threshold‑based limit. The bill phases in the new rule for products offered in interstate commerce beginning 180 days after enactment, giving manufacturers and distributors a short compliance window.
Because the bill amends existing FD&C Act language, enforcement will proceed through the FDA’s normal tools for adulterated products (recall, seizure, injunctions, civil penalties), though the statute itself does not add new penalties or novel enforcement mechanisms beyond that classification.Separately, the bill requires the FDA Commissioner, working with the Director of NIOSH, to study short‑ and long‑term health impacts from exposure to these products and to focus on salon workers and associations with cancer, respiratory issues, and endocrine disruption. The study must produce an initial report to Congress within one year and a final report roughly two years after enactment; those reports must include findings and recommendations for regulatory action and identify further research needs.
The statute also allows the Secretary to include 'similar chemical agents' that the agency determines pose comparable risks, giving FDA discretion to expand the study population and future regulatory attention beyond formaldehyde and its releasers.
The Five Things You Need to Know
The bill adds a new subsection to 21 U.S.C. 361 making any hair straightening or smoothing product that contains formaldehyde or a formaldehyde‑releasing substance 'adulterated.', The statute defines 'hair straightening or hair smoothing product' to include products intended to straighten, relax, smooth, or otherwise alter hair texture and explicitly references keratin treatments.
The law applies to cosmetics introduced or delivered for introduction into interstate commerce beginning 180 days after enactment.
The Commissioner of Food and Drugs, in consultation with NIOSH, must study health impacts of exposure on salon workers and links to cancer, respiratory issues, and endocrine disruption, and submit an initial report within 1 year and a final report within 2 years and 2 months.
The bill’s 'any amount' language creates a literal zero‑tolerance standard for formaldehyde and formaldehyde releasers in this product category rather than an analytical threshold.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title: 'Healthy Hair Act'
This is the bill’s caption; it does not affect substantive law but frames the statutory package for reference. Short titles are used in subsequent citations and reports.
Amend FD&C Act §601 — classify products as adulterated
The bill inserts a new subsection into 21 U.S.C. 361 stating that hair straightening or smoothing products containing any amount of formaldehyde or a formaldehyde‑releasing substance are adulterated. Practically, that ties this product class to the FD&C Act’s enforcement regime: FDA may act under existing statutory authorities that apply to adulterated articles. The provision’s broad phrasing ('any amount') removes de minimis defenses unless FDA establishes one through guidance or enforcement discretion.
Define 'hair straightening or hair smoothing product'
This amendment adds a definition to 21 U.S.C. 364 clarifying the targeted product scope: any product intended to straighten, relax, smooth, or otherwise alter hair texture. By including 'keratin treatment' in the bill preamble and using open‑ended language ('otherwise alter'), the definition sweeps in chemical relaxers, smoothing systems, and likely branded keratin services sold as at‑home or professional products.
Effective date for commerce
The amendment applies to cosmetics introduced or delivered for introduction into interstate commerce on or after 180 days following enactment. That creates a defined compliance window for manufacturers, importers, and distributors to reformulate or remove products from interstate commerce; it does not grandfather products already in circulation after that date.
Mandated FDA–NIOSH study and reporting deadlines
Section 3 requires the FDA Commissioner, in consultation with the Director of NIOSH, to study short‑ and long‑term health impacts of exposure to these products, specifically addressing salon workers and associations with cancer, respiratory issues, and endocrine disruption. The section mandates an initial congressional report within 1 year and a final report within 2 years and 2 months, and asks the agencies to include recommendations for regulatory action, enforcement approaches, and additional research needs. The statute also permits inclusion of 'similar chemical agents' identified by the Secretary, granting agencies latitude in study scope and future rulemaking rationale.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Salon workers and technicians — the study and adulteration designation prioritize occupational exposures and could lead to stronger protections, exposure limits, or safer product availability.
- Consumers concerned about chemical exposure — the zero‑tolerance classification aims to remove products containing formaldehyde from interstate commerce, reducing consumer exposure risk.
- Public‑health and occupational‑safety researchers and agencies — mandated studies and required recommendations will generate data and a federal roadmap for research and regulation.
- Manufacturers of formaldehyde‑free alternatives — companies selling tested, formaldehyde‑free smoothing products could gain market advantage if formaldehyde‑containing products exit the market.
- Community health advocates and clinics serving disproportionately affected populations — the bill directs federal attention to harms that often fall on women of color who disproportionately work in and use salon services.
Who Bears the Cost
- Manufacturers and importers of hair‑smoothing and keratin products — they face reformulation, testing, relabeling, withdrawal, or legal exposure if their products contain formaldehyde or releasers.
- Small salons and beauty‑service businesses — reduced product availability or higher costs for compliant supplies could raise operating expenses and complicate service offerings.
- Third‑party testing laboratories and compliance consultants — increased demand for chemical testing and certification will be a cost center for product stakeholders.
- FDA and NIOSH — the agencies must allocate staff and resources to run the mandated study, produce reports on statutory timelines, and potentially expand enforcement activity without additional appropriations specified in the bill.
- International suppliers and distributors — companies exporting these products to the U.S. market must adjust formulations or face market exclusion, complicating supply chains and trade compliance.
Key Issues
The Core Tension
The central dilemma is protecting workers and consumers from known or suspected harms by removing products that contain formaldehyde versus the practical, scientific, and market challenges of enforcing a zero‑tolerance rule: strict protection reduces exposure risk but risks regulatory uncertainty, supply shocks, litigation over definitions, and substitution toward other chemicals with less‑well‑understood health profiles.
The bill’s absolute phrase 'any amount' creates a strict legal standard but leaves open how FDA will apply analytical, enforcement, and compliance realities. Trace contamination, naturally occurring small quantities in raw materials, or non‑intended impurities may trigger formaldehyde findings; unless FDA issues technical guidance or an enforcement discretion framework, manufacturers and importers will face uncertainty about acceptable analytical limits and testing methodologies.
Similarly, the statutory inclusion of 'formaldehyde‑releasing substances' sweeps in a chemically diverse set of precursors; identifying which chemicals count as releasers will require scientific criteria and could be contested.
The study and reporting deadlines are comparatively aggressive for toxicology and epidemiology questions that often take years to resolve. The initial one‑year report will likely rely on existing literature and occupational exposure data, while the final report at just over two years may still leave causal questions unresolved.
The bill also gives the Secretary discretion to treat 'similar chemical agents' as comparable risks, which supplies regulatory flexibility but increases uncertainty for regulated firms. Finally, the statute centralizes federal authority but does not address coordination with state regulators or private‑sector certification programs, creating potential overlap or gaps in enforcement and consumer information.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.